Sport Investors League
  • Politics
  • Stocks
  • Investing
  • Business

Sport Investors League

  • Politics
  • Stocks
  • Investing
  • Business
Investing

Ocumetics Announces Completion of First Tranche of Debenture Private Placement for Net Proceeds of CA$2.82 Million

by admin May 25, 2024
May 25, 2024
Ocumetics Announces Completion of First Tranche of Debenture Private Placement for Net Proceeds of CA$2.82 Million

(TheNewswire)

Calgary, Alberta May 24, 2024 – TheNewswire .  Ocumetics Technology Corp. (‘ Ocumetics ‘ or the ‘ Corporation ‘) ( TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it has completed the first tranche of the private placement of debentures previously announced by the Corporation on May 15, 2024.

The Corporation has issued secured convertible debentures having an aggregate face value principal amount of $3,000,000 (the ‘ Principal ‘).  The debentures were subject to an original issue discount of 6%, resulting in net proceeds to the Corporation of $2,820,000 (the ‘ Net Proceeds ‘), less expenses incurred by the lenders in respect of the offering.   The debentures bear interest at a rate of 18% per annum, compounded annually.  The Debentures will mature, and Principal and interest will be payable by the Corporation, on the date which is two years from the date of issue.  The Corporation may prepay the indebtedness under the debentures at any time upon ninety (90) days prior written notice, without penalty.

Principal is convertible at the option of the holder into common shares of the Corporation at a conversion price of $0.32 per share.  Interest will be convertible into common shares of the Corporation pursuant to shares for debt applications, from time to time, at the option of the debenture holders.  The debentures are secured by a general security agreement on the personal property of the Corporation.  The debentures and the common shares issuable upon the conversion of the debentures are subject to a four month hold period.

The total offering is for up to $4,000,000 of debentures.  The Corporation intends to close the rest of the offering in one or more subsequent tranches.

100% of the Net Proceeds are expected to be used to fund the Corporation’s first in-human clinical trials and for ongoing research and development.  Although the Corporation intends to use the proceeds of the offering as described above, the actual allocation of proceeds may vary from the uses set out above, depending upon future operations, events or opportunities.

Closing of the Private Placement was subject to the conditional approval from the TSX Venture Exchange, which was obtained.

‘With tranche one of this funding in hand, we will immediately put in motion the critical steps leading to our first in-human trials in the Dominican Republic planned later this year,’ says, Dean Burns, President and CEO of Ocumetics.

About Ocumetics

Ocumetics Technology Corp. ( TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is a Canadian research and product development company that specializes in adaptive lens designs.  Ocumetics is in the preclinical study stage of a game-changing technology for the ophthalmic industry.  Ocumetics has developed an expandable intraocular lens that fits within the natural lens compartment of the eye potentially to eliminate the need for corrective lenses.  It is designed to allow the eye’s natural muscle activity to shift focus from distance to near.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Dean Burns                                Dayton Marks

President and CEO                        Director

(817) 874-7564                                (778) 347-2500

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain ‘forward-looking statements’ under applicable Canadian securities legislation.  Forward-looking statements include, but are not limited to, statements with respect to the commencement, timing and scope of the research and development to be conducted by the Corporation mentioned above.  Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include but are not limited to: operational matters, historical trends, current conditions and expected future developments, access to financing as well as other considerations that are believed to be appropriate in the circumstances.  There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.  The Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Copyright (c) 2024 TheNewswire – All rights reserved.

News Provided by TheNewsWire via QuoteMedia

This post appeared first on investingnews.com

0
FacebookTwitterGoogle +Pinterest
previous post
Antler Gold Announces Option Agreement for the Erongo Gold Project in Namibia Is Subject to TSX-V and Shareholder Approval
next post
Lindsey Graham tells UN International Court of Justice to ‘go to hell’ over ruling against Israel

Related Posts

Juggernaut Further Increases Oversubscribed Financing to $9,557,000 due...

April 26, 2025

Acceleration of RAD204 Phase 1 dose escalation trial

May 12, 2025

Strategy for Cuban Mining Joint Venture

July 1, 2024

Marvel Discovery Acquires Strategic Ground In Elliot Lake,...

May 24, 2024

Mawson Finland Limited Provides Summary of 2024 Exploration...

November 9, 2024

Amgen, Merck and Pfizer Release Latest Quarterly Earnings,...

February 5, 2025

Crescent Point to Acquire SilverBow in US$2.1 Billion...

May 17, 2024

Funding of up to C$1.3 million through Canada’s...

February 7, 2025

xU3O8 (uranium.io): Pioneering Physical Uranium Ownership Powered by...

May 2, 2025

Harvest Gold Soil Sampling Program Reveals Several New...

May 23, 2025

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent

    • Strategic Chaos or Tactical Goldmine? What QQQ’s Chart is Whispering Right Now

      June 5, 2025
    • Why ADX Can Mislead You — And How to Avoid It

      June 5, 2025
    • S&P 500 on the Verge of 6,000: What’s at Stake?

      June 5, 2025
    • Speaker Johnson surprised by Musk’s criticism of ‘big, beautiful bill’: He’s ‘flat wrong’

      June 5, 2025
    • There’s a way to aid Gaza. I know, my foundation just helped deliver 7 million meals… without incident

      June 5, 2025

    Categories

    • Business (967)
    • Investing (2,320)
    • Politics (2,873)
    • Stocks (1,054)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sportinvestorsleague.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 sportinvestorsleague.com | All Rights Reserved